மகிழ்ச்சி சிகிச்சை இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மகிழ்ச்சி சிகிச்சை இன்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மகிழ்ச்சி சிகிச்சை இன்க் Today - Breaking & Trending Today

Jubilant Therapeutics Presents Preclinical Data on its Brain Penetrant PRMT5 Inhibitor and Small Molecule PD-L1 Inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2021


Jubilant Therapeutics Presents Preclinical Data on its Brain Penetrant PRMT5 Inhibitor and Small Molecule PD-L1 Inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2021
- JBI-1527, a potent, selective oral inhibitor of PD-L1 exhibited T-cell restoration and immune-mediated tumor growth suppression
- Data support the further development of PRMT5 inhibitor JBI-778 and PD-L1 inhibitor JBI-1527 for the treatment of unmet need in oncology
BEDMINSTER, N.J., April 10, 2021 /PRNewswire/ Jubilant Therapeutics Inc., a biopharmaceutical company advancing oral, small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced that preclinical data from two programs evaluating the company s PRMT5 inhibitor and PD-L1 inhibitor as anti-cancer agents, will be presented today in a poster session at the American Association for Cancer Research (AACR) 2021 Annual Meeting taking place virtually from April 10-15, 202 ....

United States , Kostenloser Wertpapierhandel , Syed Kazmi , Dhanalakshmi Sivanandhan , American Association For Cancer Research , Prnewswire Jubilant Therapeutics Inc , Jubilant Therapeutics Inc , Jubilant Pharmova , Therapeutics Inc , American Association , Cancer Research , Chief Executive Officer , Jubilant Therapeutics , Daylight Time , Epigenetic Targets , Immune Checkpoints , Mantle Cell , About Jubilant , Jubilant Pharmova Limited , ஒன்றுபட்டது மாநிலங்களில் , சையத் காஜ்மி , அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி , மகிழ்ச்சி சிகிச்சை இன்க் , சிகிச்சை இன்க் , அமெரிக்கன் சங்கம் , புற்றுநோய் ஆராய்ச்சி ,

Jubilant Therapeutics Announces Appointment of Luca Rastelli, Ph.D. as Chief Scientific Officer


Share this article
Share this article
BEDMINSTER, N.J., March 8, 2021 /PRNewswire/ Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, announced today the appointment of Luca Rastelli, Ph.D. as Chief Scientific Officer. Reporting directly to the Chief Executive Officer, Dr. Rastelli will lead all aspects of R&D for Jubilant Therapeutics and serve as a scientific liaison for the company to investors, partners and the medical community.
Luca is a highly accomplished scientist and oncology drug developer and it is a pleasure to welcome him to the team, said Syed Kazmi, Ph.D., President and Chief Executive Officer of Jubilant Therapeutics. His experience and leadership advancing novel targeted therapeutics will be integral as we execute our corporate vision. ....

United States , Luca Rastelli , Serono Merck , Syed Kazmi , Department Of Neuro , Prnewswire Jubilant Therapeutics Inc , Kleo Pharmaceuticals , University Of Geneva , American Brain Tumor Association , Md Anderson Cancer Center , Therapeutics Inc , Chief Scientific , Chief Executive Officer , Jubilant Therapeutics , Chief Scientific Officer , Vice President , Bioxcel Therapeutics , Boston Scientifics , Merck Serono , Anniversary Translational , Molecular Biology , Jubilant Therapeutics Inc , ஒன்றுபட்டது மாநிலங்களில் , செரோனோ மெர்க் , சையத் காஜ்மி , துறை ஆஃப் நரம்பியல் ,

Jubilant Therapeutics Announces Research Collaboration with Boston Children's Hospital, Harvard Medical School, to Evaluate PAD4 Inhibitors in Autoimmune/Inflammation Disease Models


(1)
BEDMINSTER, N.J., Feb. 25, 2021 /PRNewswire/ Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced a collaboration with Boston Children s Hospital (https://wistar.org/) to evaluate peptidyl arginine deiminase 4 (PAD4) inhibitors under development by Jubilant Therapeutics to explore the modulation of neutrophil extracellular traps (NETosis) in preclinical models of neutrophil regulation and rheumatoid arthritis (RA).
PAD4 is an enzyme that converts arginine to citrulline in histones and is highly expressed in neutrophils. Histone citrullination has been implicated in the formation of NETs which is believed to contribute to pro-inflammation and disease progression in many autoimmune disorders including RA, fibrosis, lupus and ARDS. ....

United States , Kostenloser Wertpapierhandel , Syed Kazmi , Denisa Wagner , Harvard Medical School , Jubilant Therapeutics Inc , Jubilant Life Sciences , National Academy Of Medicine , National Academy Of Sciences , Program In Cellular , Prnewswire Jubilant Therapeutics Inc , Therapeutics Inc , Boston Children , Jubilant Therapeutics , Chief Executive Officer , Senior Investigator , Molecular Medicine , Edwin Cohn Professor , Harvard Medical , World Report , National Academy , Hughes Medical Investigators , Jubilant Life Sciences Limited , Medi Cal , Auto Immune , ஒன்றுபட்டது மாநிலங்களில் ,